Comparison of the “Other” Regimens for HIV-Naive Patients

Darunavir was superior to atazanavir — and raltegravir was superior to both — for the combined efficacy/tolerability endpoint, but between-regimen differences were entirely driven by tolerability.

The 2014 Department of Health and Human Services Guidelines for the Use of Antiretroviral Agents in HIV-1–Infected Adults and Adolescents recommends 10 different regimens for treatment-naive HIV-infected patients. Although all the newer regimens have been compared with nonnucleoside reverse transcriptase inhibitor (NNRTI)–based ones, the relative efficacy and tolerability of non-NNRTI–anchored regimens has not been studied in large non-company-supported trials.

In the open-label ACTG A5257 trial, 1809 treatment-naive HIV-infected adults were randomized to receive one of three regimens (once-daily atazanavir 300 mg with ritonavir 100 mg; once-daily darunavir 800 mg with ritonavir 100 mg; or twice-daily raltegravir 400 mg), all plus a once-dai…

Reviewing Author

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Comparison of the “Other” Regimens for HIV-Naive Patients

Topics

Reviewing Author